15 results about "Virus infected cell" patented technology

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.

The application provides a benzene [d] isoxazole compound and an application thereof. The compound has the structure shown in the following formula I. The benzene [d] isoxazole compound provided by the application can induce degradation of BET protein and / or GSPT1 protein, and has an anti-proliferation effect on cancer cells. Therefore, the compound and the composition provided by the application can be used for preparing a drug for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and the like.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

The application discloses a kind of targeted exosome chimeric antigen receptor molecules for treating HIV infection and its application, belong to the field of biological medicine technology.The application is packaged into targeted exosome by coding anti-HIV CAR mRNA directionally.The nano antibody sequence of targeted CD3, CD4, CD8+T receptor on T cell is fused to the N-terminal of LAMP-2B to construct specific targeting plasmid, so that the targeted peptide is expressed on the surface of exosome membrane, the expression plasmid containing RNA binding protein L7A and exosome tag protein CD63 is constructed, and the exosome loaded with CAR mRNA and targeted to T cell is obtained by three-plasmid co-transfection of HEK293F cells containing C / D box CAR plasmid.The exosome can construct human CAR-T cell when incubated with PBMC in vitro or back into humanized mouse in vivo, and has significant killing virus infected cell activity.

The application provides a kind of 2,6-piperidinedione derivatives and preparation method and application thereof.The compound has the structure shown in the following formula I, formula II or formula III:2,6-piperidinedione derivatives described in the application can induce the degradation of GSPT1 protein, and have cytotoxic effect on cancer cells.Therefore, the compound and composition provided by the application can be used for preparing drugs for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and other related diseases.

A method of culturing cells for vaccine production comprises culturing cells in the presence of microcarriers with cell culture media and infecting the cells with a virus. The microcarrier comprises a bead and a coating. The coating comprises a thermo-responsive polymer having a lower critical solution temperature (LCST) of between about 20 °C and about 34 °C. The cells adhere to the coating of the microcarrier at a temperature above the LCST. The microcarrier comprises a polymeric bead, and a hydrophobic polymer. The hydrophobic polymer is a block copolymer which is connected to the bead by a covalent bond or by physical adsorption. The block copolymer comprises at least one hydrophobic block and at least one thermo-responsive block.

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.

The invention discloses a reagent and a kit for detecting EB (Epstein-Barr) virus infection and a method for detecting EB virus infected cell lineage, and belongs to the field of medical diagnosis. The technical problem to be solved by the invention is how to accurately locate different cell lineages of EBER + cells. The reagent for detecting EB virus infection disclosed by the invention contains an EBV probe and an antibody for marking a cell lineage, the sequence of the EBV probe is shown as SEQ ID No.1 and SEQ ID No.2, and the antibody for marking the cell lineage is a CD3 antibody, a CD20 antibody and / or a CD56 antibody. The reagent and the kit for detecting EB virus infection can be used for simultaneous marking of EBER genes and antigen proteins, accurate positioning of different cell lineages of EBER + cells is achieved, and cell lineage positioning of EB virus infection is further achieved.

This invention belongs to the field of virus-infected cell line technology, and particularly relates to a striped field mouse lung cell line and its applications. The striped field mouse lung cell line has the accession number CCTCC NO: C2025268. The AaL-09W cell line (including primary and passaged cells) provided by this invention has multiple advantages, including high sensitivity to Hantavirus, high replication efficiency, high isolation success rate, closer resemblance to the host's natural environment, passage stability, and easy scaling-up. It provides a reliable cellular tool and an efficient, reliable, and scalable experimental platform for the isolation, identification, in vitro culture, titer determination, infection mechanism and pathogenesis research, new drug screening, and vaccine development of Hantavirus, meeting the needs of efficient culture and multi-scenario applications of HTNV and related Hantaviruses.

The application discloses a compound with a structural formula I, wherein the compound has good 3CL protease inhibitory activity, has significant proliferation inhibitory activity on virus-infected cells, and has potential application value in treating diseases related to virus infection. The compound has good solubility and permeability, good in-vivo metabolic stability, high in-vivo exposure, and high bioavailability, and is a potential drug compound.

The invention provides a high-throughput screening method of an anti-Nipah virus drug. The method comprises the following steps: firstly, completing drug gradient dilution and planking pretreatment in a BSL-2 laboratory; then carrying out virus infection, cell culture and 72-hour incubation in the BSL-4 core region; the method comprises the following steps: carrying out rapid and low-cost visual preliminary screening on a whole-plate sample through crystal violet dyeing, and selectively carrying out TRIzol LS inactivation treatment on a small amount of potential effective sample supernatant; after the inactivated sample is transferred to a BSL-2 laboratory, the virus copy number is accurately quantified by adopting a qRT-PCR technology, and finally the drug inhibition ratio and the EC50 value are calculated. According to the method, through a staged screening strategy, on the premise of ensuring biological safety, the screening flux is greatly improved, the detection cost is reduced, and a reliable solution is provided for drug screening of high-pathogenicity pathogenic microorganisms.

The present disclosure provides compositions and methods for inhibiting herpesvirus replication in a cell infected with herpesvirus. The composition includes a double stranded DNA molecule including a sequence of a cis regulatory sequence (crs) of a herpesvirus, wherein the crs is flanked on 5′ end by a first sequence of at least 2 base pairs and on the 3′ end by a second sequence of at least 2 base pairs.

The invention discloses a bovine nodular skin disease subunit vaccine based on P122-Fc fusion protein, and belongs to the technical field of veterinary biological products. The bovine nodular dermatosis subunit vaccine disclosed by the invention comprises a P122-Fc fusion protein and a water-in-oil-in-water type multiple emulsion adjuvant MONTANIDEISA 206 VG. According to the invention, a genetic engineering subunit vaccine technical route is adopted, the vaccine components are only recombinant proteins and adjuvants and do not contain any forms of live viruses, so that the risks of virulence reversion and vertical transmission are fundamentally eradicated; high safety is successfully combined with a high intensity, Th1 biased immune response. According to the scheme, a high-titer body fluid antibody is excited, and the body fluid antibody is necessary for eliminating virus infected cells. Systematic target animal safety tests (including pregnant cow over-dose inoculation) prove that no abortion and no significant adverse reaction exist, safe immunity to sensitive groups such as pregnant cows is achieved, and the problems that existing mainstream attenuated live vaccines have potential virulence enhancement risks, may cause abortion to pregnant cows, and are poor in immunity to pregnant cows are thoroughly solved. And the application of the feed additive in key livestock groups is strictly limited.

Provided herein, inter alia, is a recombinant herpesvirus vector genome including a heterologous herpesvirus Infected Cell Polypeptide 0 (ICP0) gene, a polynucleotide comprising the recombinant herpesvirus vector genome, and a host cell including the recombinant herpesvirus vector genome. The recombinant herpesvirus vector genome provided herein including embodiments thereof is contemplated to be useful for expressing a transgene in the host cell. In embodiments, the recombinant herpesvirus vector genome provided herein including embodiments thereof causes no detectable cellular toxicity to the host cell.

A method is provided for reducing cytokine secretion in virus-infected cells through treatment with specific alkylamides. The method includes identifying a cell infected with a rhinovirus or influenza virus and administering one or more alkylamides, such as Dodeca-2(E),4(E)-Dienoic acid isobutylamide, to reduce cytokine release, particularly interleukin-8 (IL-8). In certain embodiments, the alkylamides are in purified form and may be derived from Echinacea purpurea. The method may further comprise measuring IL-8 secretion to assess efficacy of the treatment. Another aspect provides a screening method for identifying specific alkylamides effective against respiratory virus infections by comparing cytokine secretion levels between infected cells treated with purified alkylamides and those treated with Echinacea purpurea ethanolic extract. Alkylamides demonstrating reduced cytokine secretion and a selectivity index greater than 10 are identified as therapeutic candidates for mitigating cytokine-mediated inflammatory responses in respiratory viral infections.